Nathaniel P Katz, MD Journal of Pain and Symptom Management

Slides:

Advertisements

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Advertisements

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

Analgesic and anti-inflammatory dose–response relationship of 7

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial David M. Fleischer, MD, A. Wesley Burks,

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized,

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain Richard L. Rauck, MD, Mark S. Wallace,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations Mary E. Lynch,

The Impact of Chronic Pain on Life in the Household

Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study Liliane.

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced.

David M. Simpson, MD, Lydia Estanislao, MD, Stephen J

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate.

Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial Geila Ribeiro.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Samy A. Alsirafy, MBBCh, MSc, MD, ABHPM, Dip Pall Med

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: An open-label prospective clinical trial

Got Volunteers? Association of Hospice Use of Volunteers With Bereaved Family Members' Overall Rating of the Quality of End-of-Life Care Eve M. Block,

Morphine with Dextromethorphan

A randomized, double-blind, crossover study of the use of transcutaneous spinal electroanalgesia in patients with pain from chronic critical limb ischemia

Jean-Pierre Van Buyten, MD Journal of Pain and Symptom Management

Gastrointestinal Effects of NSAIDs and Coxibs

Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study Neil A. Hagen, MD, FRCPC, Patrick du Souich,

Transdermal Fentanyl for Chronic Pain in AIDS

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial.

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Abuse Potential of Morphine/Dextromethorphan Combinations

A Comparative Review of Palliative Care Development in Six Countries Represented by the Middle East Cancer Consortium (MECC) Amanda Bingley, PhD, David.

Challenges in design and interpretation of chronic pain trials

NMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance Donald D Price, PhD, David J Mayer, PhD, Jianren Mao,

Dose-response relationship between opioid use and adverse effects after ambulatory surgery Sean Z Zhao, PhD, MD, Frances Chung, MD, David B Hanna, MS,

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

The Assessment of Cancer Pain in North India

Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial Christopher W. Kerr, MD, PhD, Julie Drake,

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate in the Management of Constipation in Hospice Patients Yoko Tarumi, MD, Mitchell P.

Which Treatment Is Better

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting Marin Golčić, MD, Renata Dobrila-Dintinjana,

Long-Term Safety of MorphiDex®

Evaluating the Quality of Dying and Death

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients Ola.

Carmen R. Green, MD, Laura Montague, BS, Tamera A. Hart-Johnson, MS

Knowledge and Attitudes of Italian Medical Staff Towards the Approach and Treatment of Patients in Pain Marco Visentin, MD, Leonardo Trentin, MD, Roberto.

A Preliminary Study of the Utility of the Brief Hospice Inventory

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel.

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized, Controlled.

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Caudal bupivacaine supplemented with caudal or intravenous clonidine in children undergoing hypospadias repair: a double-blind study T.G. Hansen, S.W.

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled.

Use of Pregabalin in the Management of Chronic Uremic Pruritus

Nausea and Vomiting Remain a Significant Clinical Problem

Physical Activity Behaviors in Individuals with Multiple Sclerosis: Roles of Overall and Specific Symptoms, and Self-Efficacy Erin M. Snook, MS, Robert.

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Presentation transcript:

MorphiDex® (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients Nathaniel P Katz, MD Journal of Pain and Symptom Management Volume 19, Issue 1, Pages 37-41 (January 2000) DOI: 10.1016/S0885-3924(99)00129-3

Fig. 1 Mean percentage of days patients experienced satisfactory pain relief during the crossover study. The shaded bar represents the MS:DM group; the open bar represents the MS group. Overall, there was no statistical difference in pain relief between the MS:DM group and MS group at any time point Journal of Pain and Symptom Management 2000 19, 37-41DOI: (10.1016/S0885-3924(99)00129-3)

Fig. 2 Average increase or decrease in morphine daily dose used to achieve satisfactory pain control over the initial 2 wk of the crossover study. The decrease from baseline in the MS:DM group was significant (P < 0.001). The increase from baseline in the MS group was significant (P = 0.007). The MS:DM group and the MS group were significantly different from each other (P < 0.001) Journal of Pain and Symptom Management 2000 19, 37-41DOI: (10.1016/S0885-3924(99)00129-3)

Fig. 3 Mean percentage of days patients experienced satisfactory pain relief during the run-in phase and during week 1, week 2, week 3, and week 4 of the parallel study. Shaded bars represent the MS:DM group; open bars represent the MS group. Overall, there was no statistical difference between the MS:DM group and the MS group at any time point Journal of Pain and Symptom Management 2000 19, 37-41DOI: (10.1016/S0885-3924(99)00129-3)

Fig. 4 Mean daily morphine dose (mg) during the run-in period (open bars) and after 4 wk (shaded bars) in patients randomized to receive MS or MS:DM. The change from the run-in period to the end of the 4-wk period measured at 16 mg in the MS group versus 1.6 mg in the MS:DM group, and was significantly different (P = 0.025) Journal of Pain and Symptom Management 2000 19, 37-41DOI: (10.1016/S0885-3924(99)00129-3)